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The effect ofhalofuginone, a plant alkaloid kn.own to 
inhibit collagen type I synthesis, on skin collagen 
content and skin Inorphology was evaluated in two 
ill vivo Inodels of scleroderma: the Inurine chronic 
graft-versus-host disease (cGvHD) and the tight skin 
Inouse. Skin collagen was assessed by hydroxyproline 
levels in skin biopsies and by iInInunohistocheInistry 
using anti-collagen type I antibodies. Daily intraper-
itoneal injections ofhalofuginone (1 p.g/Inouse) for 52 
d starting 3 d before spleen cell transplantation, 
abrogated the increase in skin collagen and pre-
vented the thickening of the derInis and the loss of 
the subderInal fat, all of which are characteristic 
of the cGvHD Inice. Halofuginone had a IniniInal 
effect on collagen content of the control Inice. The 
R ecently we demonstrated that halofuginone, an alka loid origina ll y isolated /Tom the plant Die/Iron Ie.iJriJi 'gn, suppressed av ian skin c. o ll agen synthesis iI/ • /l1/J<I [1]. In cu lture, halofug1l10n e attenuated coll a-gen production and collagen a1 (I) gene expression 
by murine and avian skin fibrob lasts without affecting cell prolif-
e ration or co llagenase ;lctivity [2]. I-1alofuginone specifically inhib-
ited collagen a1 (I) gen e express ion without afFecting the synthesis 
of other collagen types such as type II and III [2.3]. 
Although no anima l model exists that ex hibits all aspects of 
scI.eroderma , two experimental systems are avai lable that resemble 
many features of the human disease [4]. The first is the murine 
chronic graft-versus-h ost disease (cGvHD), which occurs across 
minor histocompatibility ba rrie rs [5,6] . In this model, changes 
reminiscent of scleroderma deve lop in the mou se including cuta-
neous fibrosis, loss of dermal fat, atrophy of dermal appendages, 
mast cell depletion, and a mononuclear cell in filtration [7]. T he 
second model is the tight skin (TSK) mouse, which is a spontan eous 
mutation with a single gene defect on chromosome 2 characterized 
by exaggerated connective tissue deposition in skin and multipl e 
inte rnal organs, including the lungs and heart [8-10]. The TSK 
mouse develops cutaneous hyperplasia with histopathologic and 
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halofuginone-dependent decrease in skin collagen 
content was concentration-dependent and was not 
accoInpanied by changes in body weight in either the 
cGvHD or the control Inice. Injections of halofugi-
none (1 p.g/Inouse) for 45 d caused a decrease in the 
collagen content and derInis widtb in tight skin Inice, 
but did not affect the derInis width of control Inice. 
Collagen content deterInmation froIn skin biopsies 
confirIned the iInInunohistocheInical results in the 
saIne Inice. The low concentration of halofuginone 
needed to prevent collagen deposition in fibrotic skin 
without affecting body weight suggests that halofugi-
none Inay serve as a novel and pronlising anti-fibrotic 
therapy. Key lVol'ds: collagen 0'1(I)lmflst cells. ] IIIlIest 
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bioch emical changes in skin similar to those that occur in human 
scleroderma skin [8,11] . Although lacking the inAammatory fea-
tures of the human disease, the TSK strain exhibits the excessive 
accumul ation of coll agen in skin and som e internal organs charac-
teristic of SSc [12]. Dermal fibroblast cell lin es estab lished fi'ol11 
TSK mice produce greater amounts of coll agen than fibroblasts 
established £rom litte r mate normal mice, due to inc reased expres-
sion of the genes encoding type land flI procolla gell P ·.I] . Fur-
thermore, the autoantibodies produced in the TSK mice exhibit 
specificities sim il ar to those produced in scleroderma pati ents 1'1.3] . 
To evalu ate the potential ro le of ha lofuginone as an an ti-fibrotic 
therapy in cGv HD, scleroderma, and other fibrotic di sorders , we 
studied the effect ofhalofuginone on skin coll agen content and skin 
morphology in murin e cG vHD and TSK mice iI/ "i,}{). 
MATERJALS AND METHODS 
Materials I-I ydrox y-L-proline, chloramin-T. and p-dimethyl aminoben-
za ldehyde were obtained from Sigma (St. Louis. MO) . Halofu ginol1c 
bromhydratc was obtained from Rousse ll (Paris. France). Rabbit anti-
mouse collagen type I antibodies were obtained from l3iodesign Int. 
(Kennebunk. ME). Peroxidase-conjugated goat anti-rabbit IgG fi'action was 
ohtained from Jackson (West Grove. PAl. 
Animal Models 
M II";II " eG"HD: Donor mice (H weeks old) were 1310.02 llIice (1-1_2", 
mis-b) and the recipient Illice (8 weeks old) were BALBlc mice (:IIso H_2d. 
mis-b). To induce cGv l-lD , 25 X lO" spleen ce lls fi'olll 1310 .02 llIice were 
injected intravenously into BALBI c mice that rece ived sublethal 600 R.ad 
('''Co whole body irradiation prior to transplantation [1 4 .15]. The control 
group consisted of 600-Rad-irradiated BALl3 /c recipient mice that were 
0022-202X/96/S10.50 • Copyright 1996 by The Society for investigative Dermatology. Inc. 
84 
VOL. 106. NO. I JANUARY 19% 
cransplanted with 25 X 10" syngeneic splenocytes . FoUowing u'ansplanta-
tion, mice were maintained in laminar flow hoods. Three days before 
transp lantation and throughout the experiment, mice were injected intrap-
eritoneally with halofuginone as indicated. During the experiments, 
changes in body weight were recorded. Mast cell s (MC) were isolated from 
the mouse peritoneal cavity, purified, and counted by a procedure described 
previously [1 5] . 
TSK iHice: Five-week-old TSK/+ and syngeneic +/+ mice (C57B1/ 
6[sk/ + and C57B1I6 + /+) were obtained from Jackson Laboratories (Bar 
Harbor, ME) and housed in the Hadassah University Hospital f.1cilities. 
Mice were injected inrmpcritoneaJl ), with halofuginone as indicated. 
Preparation of Skin Sections and hnnlnnohistochelnistry Sk.in 
biopsies obta ined from mouse abdomen were collected into phosphate-
buffered saline (PBS) and fixed ovemight in 4%, paraformaldchyde in PBS at 
4°C. Serial 5-lJ-m sections were prepan:d afte r t.he samples had been 
dehydrated in graded ethanol solutions, cleared in chloroform, and embed-
ded in Paraplast. The sections were depanllFinized in xylene, reh)'drated 
through a graded series of graded ethanol solutions. rinsed in distilled water 
(5 min) , and incubated in 2 X SSC at 70°C for 30 min. The sections were 
then limed in distilled water and treated with pronase (0.125 mg/ml in 
50mM Tris-I-I C I. 5 mM ethylenediaminetetraacetic acid, pH 7.5) for 10 
min . After digestion. slides were linsed in disti lled watcr, postfixed in 10% 
formalin in PBS . blocked in 0.2% glycine, rinsed in distilled water, rapidly 
dehydrated through graded ethanol solu tions. air-dried for several hours, 
and stained by hematoxylin-eosin . For immunohistochemistry, the collagen 
type J antibodies were used in I :40 dilu tion and the peroxidasc-conjugated 
goat anti-rabbit in 1 :50 dilution. 
Skin Collagen Determination Skin biopsies were hydro lyzcd for 22 h 
at 110°C with G N HC!. Nitrogen was determined after Kjeldahl digestion 
by the spectrophotometric procedure using an autoanalyzer as described 
previously Ill. The collagen-un ique amino acid hydroxyproline was deter-
mined [1 6] and the results are expressed as collagcn/ total proteins. 
RESULTS 
Skin Collagen Content in cGvHD Mice Is Reduced by 
Halofuginone In pre (jminary experiments, BALB/c mice (ten 
per group) were injected daily with 1 mg/ mouse of either halofug i-
none or sa line for 45 d. After 21 and 45 d of treatment, skin biopsies 
were taken for collagen determination. After 21 d of treatment, no 
changes in the skin collagen conte nt were observed in the treated 
mice compared with the controls. After 45 daily injections there 
was a sigrti6 cant reduction in skin collagen content (from 0.46 ::t:: 
0.02 collagen /protein in the control mice to 0.35 ::t:: 0.02 coLlagenl 
protein in the halofuginone-treated mice). 
In the subsequent experime nt, 3 d before transplantation and 
52 d thereafter, cGvHD mice were injected intraperitoneaUy daily 
with 1 f.Lg/mouse of halofuginone. The control g roup (BALBlc 
mice transplanted with syngeneic splenocytes) was injected with 
the sam e dose of halofuginone . Every few days body weight was 
recorded, and at 45 and 52 d after transplantation, peritoneal cavity 
MC number was recorded and abdomen skin samples were taken 
for collagen content determination and for immunohistochemistry 
using anti-collagen type I antibodies . 
Reduction in body weight i.n both cGvHD and control mice was 
o bserved following transplantation. However, 10 d after transplan-
tation the control mice started to gain weight, and their body 
weight returned to the level before transplantation, whereas the 
body weight of the cG vHD mice remained low longer and reach ed 
the control level only after 52 d. Halofuginone had no efFect on 
body weight of the cGvHD or the control mice (data not shown). 
Another ch aracteristic of the cGvHD mice is the reduction in 
peritoneal cavity MC number, which correlates with the appear-
ance of fibrosis [15]. Halofuginone treatment did not affect MC 
number in the cGvHD or the BALB/c controls (data not shown), 
w hich may indicate the specific ity of ha lofuginone's action. 
The skin co llagen content 45 and 52 d following transp lantation 
was significantly high er in the cGvHD mice than in the BALB/c 
controls (Fig 1). Halofuginone treatment (1 f.Lg/mouse/d) abol-
ished the increase in skin co llagen content observed in tbe cGvHD 
mice, with 110 or minimal effect on collagen content of the control 
mice (days 45 and 52, Fig lA,B, respectively). 
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Figure 1. Skin collagcn content of BALB/c controls and cGvHD 
nlice is rcduced by halofuginone. Mice were injected daily with 
halofugillonc (l IJ-g/ mouse). After 45 (A) and 52 (B) d. abdominal skin 
biopsies were taken for collagen and protein determination. Each skin 
sample was hydrol)'zed separately and hydroxyproline and rlicrogell were 
determined from the individual tubes . The results. expressed as collagell/ 
tota l proteins of each sample. are the mean :!: SEM . III each group n = S. 
Halo., halofuginoll c 
Development of cGvHD was <lssociated with severe loss or total 
Jbsel1ce of subdermal fat, thickening of the dermis. and increase in 
fibrosis (Fig 2A, control ; Fig 2C, cGvHD) . Injection ofhalofugi-
none ("I f.Lg / m o use) to cGvHD mice daily for 52 d prevented tile 
development of fibrosis, thickening of the dermis , and loss of 
subderm al fat seen in the untreated cGvHD mice (Fig 2C, cGvHD 
controls; Fig 2D, cGvHD treated with halofuginone) . In contrast, 
no changes in skin morphology were observed in the BALB /c 
control mice treated with halofuginone (Fig 2A, BALB/ c controls; 
Fig 2B, BALB/c treated with halofuginone). Chronic GvHD was 
specifically associated with an in crease in collagen type I content, as 
demonstrated by using m o use collagen type I antibodies (Fig 2E, 
BALB/c controls; Fig 2G, cGvHD). Halofuginone treatment 
prevented the increase in co ll agen type I con tent in skin as 
determined in biopsies taken from cGvHD mice (Fig 2H), and 
attenuated the col.1agen type 1 content of the BALB I c con tro ls (Fig 
2F). 
Skin Collagen Content in cGvHD Mice Is Inhibited by 
Halofuginone in a Concentration-Dependent Manner The 
effect of ha lofuginone on skin coll agen co n tent was concentration 
dependent. In the control BALBl c mice, concentrations as low as 
0.2 f.Lg/d/mouse ofhalofuginone-attenuated skin collagen content 
(Fig 3A, BALB/c untreated; Fig 3B, BALB / c o'eated with 0 .2 
fLg/d/mouse). Inj ection of 1 f.Lg / mouse daily o r every other day 
decreased skin collagen content further (Fig 3C,D). [n the cGvI-lD 
mice, 0.2 f.Lg/ d / mouse of halofuginoll e prevelJted the loss in 
subcutaneous fat and partially prevented tile increase in skin 
collagen content (Fig 3E, cGvHD controls; Fig 3F, cGvHD 
treated with 0.2 f.Lg/d<ly / mouse). Inj ection of 1 fLg/ mouse d<li.l y 01' 
every oth e r day decreased skin collagen cOntent further without 
affecti ng the subcutaneous fat (Fig 3G,H). These results corre lated 
weU with dctel'll1ination of collagen content in skin biopsies taken 
from the cGvHD mice (Fig 4). After -+5 d of halofuginone 
treatment, a concentration-dependent decrease in skin coll agen 
content was observed, reaching a maximum of 35'1., reduc tion in 
skin collagen content when 1 mg/ m o llse of h alofugin one was 
injected every other day (Fig 4). 
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Figure 2. Halofu g inon e p reven ted the loss of subc u taneous a dip ose ti ssu e and reduced skin collagen conten t in c GvHD mice . H alofuginonc 
(1 ILg/mouse) was injected da il y to llALB/c control and GvHD mice. After 52 d . ski n b iopsies were collected. and 5 J.l.m sections were prepared for staining 
with hematoxylin-eosin (A- D) or for immuno histochemistry using anti-mouse coll age n type I antibodies (E-H). A,E, I3ALB/c controls : B,F, I3ALB/c 
controls treated with ha lofuginone; C,D. cGvl-l D mice; D ,H, cGvHD mice treated w ith halofuginonc. Note the dermal (0) thickening and rep lacement of 
subcuta neous ad ipose tiss ue (AT) by homogeneous stained collagen (an'o",s) in the cGv l-l O compared w ith the BALBlc controls. H alofugino nc treatl11en! 
prevented the loss of subcutaneous ad ipose tiss ue and led to a red uction in the den nis thickn ess and in the staining for co llagen type 1 (D,H). Red uction in 
the srain ing fo r co llagen type 1 was also observed in the BALBlc controls (F) without changes in the tissue mo rphology (B). CONT, control; HALO, 
halofuginone. 
CO NT . 0.2 ~g/day I~g/day 1~g/2 days 
Figu re 3 . Halo fu g ino n e preven ted th e loss of subc uta n eou s adi p ose t issu e and re duced skin coHagen cont ent in c G vHD n,ice in a 
con cen tra t ion-d epen d ent m anner. I-Ia lofuginone was injected to I3ALl3 /c contro l (A-D) and cGvHD (E-H ) mice at doses of 0.2 J.l.g/ d (B,1") , 1 ILg/ d 
(C,G), and 1 J.l.g eve ry other day (D,H). After 52 d, skin biopsies we re collected and 5-/Lm sections were prepared for immunohistochemistry using 
anti-mouse coll agen type I antibodies. Notl! the dermal (0) thicken ing and rep lacemellt of subcu taneo us adi pose tissue (AT) by ho mogeneous stained 
co ll agen (ar,..,,,,s) in the cGv H D compared w ith the BALBlc controls. H alofugino ne treatment was associated w ith " decrease in collagen-spec ifi c sra ining 
in both the BALB/c and the cGvl-lD mice. T he space between the co ll agen bundles increases and co ll agen appears less packed than in thc untreatcd micc. 
In add itio n, in the cGvHD m ice halofuginoll c trcatm en t preven ted the disap pearance of the adipose tissuc. CO NT , con tro l, no treatment. 
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Figurc 4. Skin collagcn contcnt ill cGvHD micc is rcduccd by 
halofuginonc in a dosc-dcpcndcnt manncr. Halo fugillone was in-
jected to cGv HD mice at doses of 0.2 J..Lg/d, 1 J..Lg/ d, or 1 J..Lg every other 
day. After 30 d , abdominal skin biopsies were taken for collagen and protein 
de termination. Each skin sample WaS hydrolyzed separately, and hy-
droxyproline and nitrogen were determined fi'o lll the individual tubes. The 
results, expressed as co Lla gellltotal proteills of each sample. arc mean ± 
SEM. In each group n = 8. 
Skin Collagen Content in TSK Mice Is Reduced by 
Halofuginone A major chara cte ri sti c of the TSK mice is the 
in crease in d ermis width (Fig SA, contro l; Fig SD, T SK), which is 
a result o f th e increase in colla gen de positio n (Fig SE, con trol ; Fig 
5G, TSK) . Daily inj ectio ns ofhalofug ino n e (1 /Lg/m o use for 45 d) 
reduced the dermis width in T SK mice (Fig SD) witho ut affecting 
it in the control mice (Fig SB). H a lo fu g in one treatment at tenuated 
skin coll agen content in both the contro l and TSK mice (Fig 
SF,H) . C oll agen content de te rmination in skin biopsies taken from 
[h e sam e mice confirmed th e immunohistochemi cal findin gs. The 
T SK mice had hig he r le ve ls o f skin collage n than did the contro ls 
(Fig 6) . Halofu g ino ne treatment bro ught abo ut a decrease in the 
collagen con tent in b oth the control and TSK mi ce (Fig 6) . 
DISC USSION 
Drugs that inhibit fibrobla st pro life ration [17 ,18], cytokines that 
inhibit collagen synthesis [19], inhibitors of collagen c ro ss-linking 
[20] , and inhibito rs o f key e nzym es of coll agen m e tabo lism [21 ,22] 
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were all tri ed in a ttempts to redu ce skin co llagen d epositio n . 
Unfortunate ly. all th ese compo unds are n o t coll agen- type specific. 
[n additio n , the re a re serio u s concerns abo u t the toxic conse-
q ue nces of in ter fe ring with the bi osyn thesis of oth e r v ital collage-
no us m o lecul es such as C 1q compo n cn t of th e classical path way of 
comple m ent, the acetylcho line estera se of th e n e uromuscular junc-
tio n endplate, con glu tinin , and pulmo nary surfactant ap o protein , 
e tc. H alo fu gino n e, o n the o thc r h and , specifical ly iJlhibi ted coll a-
gen cd (I) gcne expression w itho u t affecting th e synth esis of o th cr 
collagen types [2,3] , cell pro life ra tio n , o r co llagenase activ ity [2]. 
To e va luate th e potential ro le of h alo fu g ino n e as an anti- fi bro lic 
th e rapy, w e used au induced (cGvH D mice) and genetically 
transmit ted (TSK mice) fIbrosis, the skin les io n s of w hi ch resem bl e 
scl e rode rm a. Because hal o fu gino n e w as fo und to inhibit coll agen 
Q'1 (I) gen e cxpress io n [2,3] , it was administered to the cGvHD 
mice 3 d prio r to spl een cell transpl an ta tiou . T h e results o b ta ined 
are con sistent w ith h alo fu g ino n e ' s mode of action . T h e e ffect of 
halofug ino ne is more pro no un ced when collagen type I gcn e 
expressio n is elevated . Once collagen is synth esized and secreted to 
the cx tracellular space, ha lo fu gin o n e can n o lo nger a ffect its 
m e tabo lism [2 ). N o explan atio n can b e offe red at present with 
regard to the supe rior e ffec t of b alo fu gi nonc o n skin coll agen 
content w he n injec ted e ve ry o th e r day, compared w ith every day. 
T he reduction in skin collagen induced by halofugino n e trcat-
m e n t was n o t accompanie d b y any changes in b od y weig h t in th e 
BA LB /c o r cGvHD mice. T his is in agreem cn t w ith o ur p revio u s 
study in which chicken s fe d die ts supple m e n ted w ith h alofu gin o n e 
for 7 w eeks star ting imm ediately afte r hatchiJlg exhibi ted a COIl-
centratio n-dep endent decrease in skin collagen con tent, w itho ut 
any changes in fecd effi cie ncy o r bod y weig h t [1] . T he d ata su ggest 
that halo fug in o ne affects m ainly skin type T coHagen syn th esis 
with o u t a ffecting o the r collagen type I-conta ining t issues. such as 
bo nes. T he expression o f type L collagen gen es fo llows a specifi c, 
discre te, and ti ssu c- specific pattern , and cell-specific transcription al 
facto rs were sugges ted to regul ate the collagen type 1 gen es [23,24] . 
Fo r example, a specific sequ en ce was fo und w ithin the proQ'2(1) 
coll agen pro m o te r which , in transgenic mice, sh owed preferential 
ac ti v ity in tai l and skin w it h a lo w activi ty in bo n e [25]. In add itio n. 
ti ssue- specific pro m oter seque n ces were ide n tified th at cOll tro l 
fib roblasts' collagen a l (I) gene [26,27]. T his m ay suggest tissue-
sp ecific regulato ry seque nces at this region of coll agen 0'1 (I) 
TSK TSK + HALO 
Figurc 5. Haiofuginonc prcvcntcd thc incrcasc in dcrmis thickncss and rcduccd skin collagcn contcnt in TSK micc. Halofuginone (1 
J..Lg/mouse) was injected daily fo r 45 d, afte r which skin biopsies were co llected and 5- /Ltll sections werc prepared for stain ing with hematoxylin-eosin (A-D) 
or for immunohistochemistry using an ti-mouse collagen type I antibodies (E-H). A,E, untreated C57B 1 16+ 1 + Ill ice: B,F. halofugino lle-treatcd 
C57B1 /6 +1+ mice ; C,G, untreated TS K mice; D, H, halo fugillol1 c- treated TSK mice. Note the increase in the dermal thickness of the TSK mice (e) 
compared with the C5 7J31 16 + 1 + Illice (A ). 0, dennis; AT , adipose ti ssue. CO NT. cOlltrol, 110 treatment: HALO, halofuginone. 
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Figure 6. Skin collagen content in TSK mice is reduced by 
halofuginone. Mice were injec te d d aiIy with h a lo fu g ino n e (1 J.Lg/ m o u se). 
Afte r 45 d abdo min a l skin bi o p sies w e re ta ke n fo r collagen and protein 
d ete rminati o n . Eac h skin sample w as h ydro lyzed separate ly and h y-
droxyp rolin e and ni trogen we re d e te rmin ed fro m th e individual tubes . T h e 
resul ts , w hi ch are expressed as collagen / total pro te ins o f e ach sample, a rc 
m ea n ::!: SEM . [n ench g ro up n = 4. H alo . h nlofu g in o n e. 
pro moter , whi ch can expl ain th e specifIcity o f ta rge t tissues fo r 
haJo fu gin o ne actio n. 
H alofuginone fuLfIll s th e criteria for successful and effective 
an ti-fibro ti c the rapy. Ex trem ely low concentra tions of hal o fu gi-
no ne arc needed to inhibit fIbro bl as ts' coll agen a l(l) synthesis at 
th e transcrip tional level, regardless of animal species [2,3] . T he 
dru g exerts its effect on skin coll agen content at co ncent ratio ns that 
do not afFect body gro wth [1] o r MC number, which is a charac-
teristic o f cGvHD . In additi on , a treatm ent regimen can be 
designed that will inhibit only overproduction of collagen type I 
synthesis w ithou t affec ting no rmal collage n syn thesis (Fig 1) . 
C urren tly, patients with scle rode rnul are trea ted with anti-inflam-
m ato ry and/or anti flbrotic agents. D -penicillamine is amo ng the 
m ost important anti fibroti c agents used [20,28J because it blocks 
intra- and interchain crosslinking in the ne wly form ed collagen 
m o lecul es 1"29] . D ecrease in collagen synthesis by halofugino ne 
might be m o re e ffective than attempting to treat the consequ ences 
of collagen o verproducti on . 
1n conclusion, the results of this study sugges t tha t halofuginon e 
is a pro mising novel anti-fibro tic the rapy . 
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